Larimar Therapeutics Inc.
Organization details
- Legal name
- Larimar Therapeutics Inc.
- Former names
- Zafgen, INC.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Bala Cynwyd
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LRMR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001374690
- EIN
- 20-3857670
- Wikidata ID
- Q30269406
Board of directors
-
Carole Ben-Maimon · Director · President and CEOSince 2023
-
Frank E. Thomas · DirectorSince 2023
-
James E. Flynn · DirectorSince 2023
-
Jeffrey W. Sherman · DirectorSince 2023
-
Jonathan S. Leff · DirectorSince 2023
-
Joseph Truitt · DirectorSince 2023
-
Thomas Edward Hamilton · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 19, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.1%
-
88.6%
-
89.3%
Board connections
6 of this board's directors also sit on 5 other boards. 3 are in the same sector.
- via James E. Flynn and Jonathan S. Leff
- via Thomas Edward Hamilton
-
Century Therapeutics Inc. Same sectorvia Joseph Truitt
-
Spero Therapeutics Inc. Same sectorvia Frank E. Thomas
-
Xeris Biopharma Holdings Inc. Same sectorvia Jeffrey W. Sherman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $25,717,000
- 8 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 29, 2026 | Harlow John B. Jr. Officer (President and COO) | Grant or award | +50,000 | — | — |
| Jul 6, 2026 | Thomas Edward Hamilton Director | Open-market purchase | +50,000 | $3.34 | $167,000 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. Director, 10% owner, * Director by Deputization | Open-market purchase | +1,084,010 | $5.00 | $5,420,050 |
| Feb 27, 2026 | Thomas Edward Hamilton Director | Open-market purchase | +100,000 | $5.00 | $500,000 |
| Feb 27, 2026 | Frank E. Thomas Director | Open-market purchase | +5,000 | $5.00 | $25,000 |
| Feb 27, 2026 | Jeffrey W. Sherman Director | Open-market purchase | +5,000 | $5.00 | $25,000 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. Director, 10% owner, * Director by Deputization | Open-market purchase | +1,084,012 | $5.00 | $5,420,060 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. Director, 10% owner, * Director by Deputization | Open-market purchase | +831,978 | $5.00 | $4,159,890 |
| Feb 27, 2026 | Deerfield Mgmt HIF, L.P. Director, 10% owner, * Director by Deputization | Open-market purchase | +2,000,000 | $5.00 | $10,000,000 |
| Jan 26, 2026 | Shankar Gopi Officer (Chief Development Officer) | Grant or award | +25,637 | — | — |
| Jan 26, 2026 | Clayton Russell Officer (Chief Medical Officer) | Grant or award | +25,637 | — | — |
| Jan 26, 2026 | Carole Ben-Maimon Director, Officer (President and CEO) | Grant or award | +100,100 | — | — |
| Jan 26, 2026 | Celano Michael Officer (Chief Financial Officer) | Grant or award | +37,604 | — | — |
| Jul 31, 2025 | Deerfield Mgmt HIF, L.P. Director, 10% owner, * Director by Deputization | Open-market purchase | +3,387,529 | $3.20 | $10,840,093 |
| Jul 31, 2025 | Deerfield Mgmt HIF, L.P. Director, 10% owner, * Director by Deputization | Open-market purchase | +3,387,539 | $3.20 | $10,840,125 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Larimar Therapeutics Inc.
Who is the CEO of Larimar Therapeutics Inc.?
Carole Ben-Maimon is Larimar Therapeutics Inc.'s President and CEO.
How many directors are on Larimar Therapeutics Inc.'s board?
Larimar Therapeutics Inc.'s board has 7 directors: Carole Ben-Maimon, Frank E. Thomas, James E. Flynn, Jeffrey W. Sherman, Jonathan S. Leff, Joseph Truitt and Thomas Edward Hamilton.
Are Larimar Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Larimar Therapeutics Inc. insiders bought $25.7 million of shares in 8 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="larimar-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.